Tirzepatide improves blood sugar control in metformin-refractory type 2 diabetes

1. In this randomized controlled trial, tirzepatide produced substantially greater reductions in HbA1c, body weight, waist circumference, and BMI than intensified conventional care (ICC) in adults with early type 2 diabetes inadequately controlled on metformin.

2. A significantly higher proportion of participants treated with tirzepatide, compared with ICC, achieved normoglycemia (HbA1c <5.7%).

Evidence Rating Level: 1 (Excellent)

Study Rundown: Early improvement in glycemic control following a diagnosis of type 2 diabetes (T2D) is associated with better long-term outcomes, including lower risks of microvascular and cardiovascular complications. However, standard-of-care management often results in progressive worsening of glycemic control as β-cell function declines. Tirzepatide has been shown to substantially increase the likelihood of achieving normoglycemia in individuals with shorter diabetes duration, while also improving insulin sensitivity, β-cell function, and multiple cardiometabolic markers. This study examined whether initiating tirzepatide in patients with early T2D and poor glycemic control despite metformin could produce more effective and durable outcomes than intensive conventional care (ICC). Over two years, participants starting tirzepatide achieved greater improvements in HbA1c and fasting serum glucose than those receiving ICC. A larger proportion of tirzepatide-treated patients also reached recommended glycemic targets, suggesting a more robust and sustained treatment effect. Weight-related outcomes similarly favored tirzepatide. Patients receiving tirzepatide experienced more substantial weight loss, and a greater share achieved clinically meaningful weight-reduction thresholds. Reductions in BMI and waist circumference were also more pronounced in the tirzepatide group, indicating broader metabolic benefits. Adverse events occurred frequently in both treatment arms, with gastrointestinal symptoms being the most common. Although the open-label design limits generalizability and may introduce bias, the overall findings indicate that early initiation of tirzepatide may provide superior glycemic and metabolic control compared with conventional intensified management. These results support considering tirzepatide as an early therapeutic option for optimizing outcomes in patients with T2D.

Click to read this study in AIM

Relevant Reading: Achieving Normoglycemia With Tirzepatide: Analysis of SURPASS 1–4 Trials

In-Depth [randomized controlled trial]: This randomized controlled trial evaluated the efficacy and safety of tirzepatide versus intensive conventional care (ICC) in adults with early type 2 diabetes (T2D) who had not achieved adequate glycemic control with lifestyle measures and metformin. Eligible participants were at least 18 years old, diagnosed within the previous four years, had HbA1c levels of 7.0%-9.5%, a BMI of 25-45 kg/m², stable weight, and stable metformin therapy. Key exclusions included type 1 diabetes, pancreatitis, advanced diabetic eye disease, inability to safely target an HbA1c ≤6.5%, and severe renal impairment. A total of 794 participants were randomized to tirzepatide (n=398) or ICC (n=396); 89% completed the 104-week analysis. Baseline characteristics were similar between groups, with a mean age of 53.5 years, mean diabetes duration of 2.6 years, mean HbA1c of 7.81%, and mean BMI of 35.4 kg/m². At 104 weeks, tirzepatide produced a greater mean HbA1c reduction than ICC (−1.99 vs. −1.32 percentage points), demonstrating clear superiority (estimated treatment difference [ETD], −0.68; p<0.001). Tirzepatide lowered mean HbA1c to 5.56% compared with 6.35% with ICC. A higher proportion of tirzepatide-treated participants achieved targets of <7% (86%), ≤6.5% (80%), and <5.7% (60%) compared with ICC. Tirzepatide also resulted in larger reductions in fasting serum glucose (ETD, −0.81 mmol/L) and substantially greater weight loss (−13.8 kg vs. −5.9 kg; ETD, −8.0 kg; p<0.001). More participants receiving tirzepatide achieved weight-loss thresholds of ≥5%, ≥10%, and ≥15%. Improvements in waist circumference (ETD, −6.2 cm) and BMI (ETD, −3.3 kg/m²) similarly favored tirzepatide. More than half of participants receiving tirzepatide achieved a composite outcome of HbA1c ≤6.5%, at least 10% weight loss, and no significant hypoglycemia, compared with only about one-fifth of those in the ICC group. Subgroup analyses showed larger HbA1c improvements in participants with higher baseline HbA1c or BMI, and greater weight loss among those with shorter diabetes duration. Treatment-emergent adverse events were common in both groups (75% tirzepatide; 69% ICC), with gastrointestinal symptoms most frequently reported. Overall, tirzepatide demonstrated superior glycemic and metabolic benefits compared with ICC in early T2D.

Image: PD

©2026 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.